
Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.
Learn how to identify chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation using blood eosinophil (EOS) levels, understand the associated risks, and recognize factors that may influence EOS counts.
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

September 25th marks this year’s observance and celebration of World Lung Day!
Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.
Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.